Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your blood test shows a certain level of a liver enzyme called AST — above 17 U/L if you are a woman, or above 20 U/L if you are a man (this requirement may not apply if you had a qualifying liver biopsy within the last 12 months — confirm with trial site).
- A special liver scan (MRI) shows that at least 8% of your liver is made up of fat, and this scan must be done within 4 weeks of your first study visit.
- You have type 2 diabetes managed by diet alone or diet plus the medication metformin (at a stable dose for at least one month before screening), OR you have three or more features of metabolic syndrome, such as high blood sugar, high blood pressure, high triglycerides, low "good" cholesterol (HDL), or being overweight/obese with a larger waist size.
- Other eligibility requirements may also apply — confirm with the trial site.
Who may not be able to join:
- You have taken part in another clinical trial for liver disease (MASH) or weight loss in the last 3 months.
- You have taken part in any other clinical trial within the last 3 months (or longer, depending on the treatment used).
- You are pregnant, trying to become pregnant, or currently breastfeeding.
- Your body mass index (BMI) is below 18 or above 45.
- You regularly drink more than a moderate amount of alcohol (more than about 1.5 drinks/day for women or 2 drinks/day for men) within the past year.
- A urine drug test comes back positive for amphetamines, cocaine, opiates, or cannabis.
- You have been diagnosed with, or are suspected to have, severe liver scarring (cirrhosis) or signs that your liver is not working properly.
- You have another chronic liver condition, such as hepatitis B or C, autoimmune hepatitis, or certain other liver diseases.
- You have had a heart attack, severe chest pain (unstable angina), or stroke in the last 3 months.
- Your blood pressure is not well controlled (above 160/100 mmHg).
- You are currently taking certain medications that could interact with the study drug (confirm with trial site).
- You are unable to have an MRI scan for any reason.
- Other exclusion criteria may also apply — confirm with the trial site.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kavita Juneja, MD, Corcept Therapeutics
Phone: (573) 882-5864
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in fasting hepatic lipogenesis after 6 weeks of treatment; Change in peak lipogenesis after 6 weeks of treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.